Greater dose-ranging effects on A1C levels than on glucosuria with LX4211, a dual inhibitor of SGLT1 and SGLT2, in patients with type 2 diabetes on metformin monotherapy.
In patients with type 2 diabetes, higher dose ranging effects on A1C levels than glucosuria with LX4211, a dual inhibitor of SGLT1 and SGLT2 on metformin monotherapy.